DiaMedica Therapeutics Inc. (DMAC)

USD 4.82

(-7.31%)

Market Cap (In USD)

206.1 Million

Revenue (In USD)

-

Net Income (In USD)

-19.38 Million

Avg. Volume

58 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.14-5.74
PE
-
EPS
-
Beta Value
1.456
ISIN
CA25253X2077
CUSIP
25253X207
CIK
1401040
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Dietrich John Pauls MBA
Employee Count
-
Website
https://www.diamedica.com
Ipo Date
2012-08-03
Details
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.